In a multicenter randomized trial, tenecteplase did not improve vision recovery compared with aspirin when given within 4.5 hours of acute central retinal artery occlusion (CRAO). The ...

Intravenous tenecteplase administered within 4.5 hours after onset of central retinal artery occlusion does not improve vision recovery at 30 days compared with oral aspirin, according to a study ...

Central retinal artery occlusion (CRAO) is an ophthalmic emergency that usually leads to sudden and permanent blindness, and ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

Please provide your email address to receive an email when new articles are posted on . The study included 72 individuals with ischemic stroke given alteplase and tenecteplase. No significant time ...

Vision recovery similar at 30 days, consistent with other recent randomized studies ...

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Intravenous tenecteplase does not improve vision recovery and is associated with greater incidence of adverse events ...